

T-
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18, C07K 14/50	A1	(11) International Publication Number: WO 99/26648 (43) International Publication Date: 3 June 1999 (03.06.99)
(21) International Application Number: PCT/US98/24806 (22) International Filing Date: 20 November 1998 (20.11.98) (30) Priority Data: 60/066,286 20 November 1997 (20.11.97) US (71) Applicant (for all designated States except US): SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KOLESNICK, Richard [US/US]; Apartment 18A, 343 East 74th Street, New York, NY 10021 (US). FUKS, Zvi [US/US]; 345 East 68th Street, New York, NY 10021 (US). HAIMOVITZ-FRIEDMAN, Adriana [US/US]; Apartment 6K, 401 E. 89th Street, New York, NY 10128 (US). (74) Agent: ADLER, Benjamin, A.; McGregor & Adler, 8011 Candle Lane, Houston, TX 77071 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: BASIC FIBROBLAST GROWTH FACTOR TREATMENT OF SEPSIS (57) Abstract The present invention provides a method of inhibiting the generation of ceramide from sphingomyelin comprising the step of administering a pharmacologically effective dose of basic fibroblast growth factor to an animal in need of such treatment. Also provided is a method of treating a pathophysiological state characterized by endothelial apoptosis, comprising the administration of a pharmacologically effective dose of a fibroblast-inhibiting cytokine to said animal.		